Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts Delcath Systems, Inc. an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of two investigator-initiated trials-in-progress abstracts on May…
Octave Bioscience Accelerates Precision Neurology Momentum, Appoints Zachary Fernandes as VP of Business Development to Scale Strategic Partnerships Octave Bioscience, Inc., a commercial stage precision medicine company pioneering biomarker-driven solutions for multiple sclerosis, Parkinson’s and other neurodegenerative diseases, today announced…
NASA Selects Astrolab to Provide Lunar Rover for Artemis Astronauts’ Return to the Moon Venturi Astrolab (Astrolab) announced that NASA has selected the company as one of two providers of a crewed lunar rover for the Artemis program, advancing the…
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure Biocytogen announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences,…
Aphios Corporation Announces Notice of Allowance for Novel Bryoid Composition Patent Targeting Alzheimer’s Disease, Multiple Sclerosis, HIV Latency and Cancer Aphios Corporation announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a…
Foundation Medicine Showcases Innovation at 2026 ASCO® Annual Meeting Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced it will showcase data across its portfolio of high-quality comprehensive genomic profiling tests at the 2026 American Society of Clinical Oncology (ASCO)…
SAGA Diagnostics to Present Data on Ultrasensitive Pathlight™ MRD Test in Breast, Colon, and Rectal Cancers at ASCO 2026 SAGA Diagnostics, a pioneer in ultrasensitive molecular residual disease (MRD) detection and precision oncology, announced that the company and key collaborators…
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as the first TROP2-directed antibody-drug conjugate for first-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates AstraZeneca and Daiichi Sankyo’s DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for…
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under…
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline Bristol Myers Squibb announced the presentation of data from its oncology portfolio and pipeline at the 2026 American Society…
Flatiron Health Brings 25+ Research Acceptances and Next-Generation Capabilities to ASCO 2026 Flatiron Health announced its presence at the American Society of Clinical Oncology (ASCO) Annual Meeting happening from May 29 – June 2, 2026, in Chicago, Illinois. Flatiron’s high-quality…
Artera Presents Multiple ASCO 2026 Abstracts on Multimodal AI (MMAI) Risk Stratification and Treatment Decisions in Cancer Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will present multiple abstracts at the 2026 American Society of…